2 days ago
Intellia (NTLA) Shares Drop Despite Breakthrough Phase 3 Gene Editing Success
Intellia (NTLA) stock dropped 3% despite positive Phase 3 results showing 87% attack reduction. FDA submission underway with 2027 launch target.
The post Intellia (NTLA) Shares Drop Despite Breakthrough Phase 3 Gene Editing Success appeared first on Blockonomi.
Source: Blockonomi →Related News
- 7 hours ago
Ondo Finance and Broadridge Unite to Bring Proxy Voting to Tokenized Stocks
- 9 hours ago
Securitize and Computershare Enable Tokenized Equity Issuance for Over 25,000 U....
- 12 hours ago
Should You Buy Advanced Micro Devices (AMD) Stock Ahead of Tuesday Earnings? Wal...
- 12 hours ago
Robinhood (HOOD) Stock Plummets 14% as Crypto Revenue Crashes 47%
- 12 hours ago
Seagate (STX) Stock Soars 10% as Analysts Target $1,000 Following Stellar Q3 Res...